CRISPR Therapeutics AG $ 83.61 -0.03 (-0.04%)
Warning! GuruFocus has detected 2 Severe warning signs with CRSP. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for CRISPR Therapeutics AG () from 2016 to Oct 01 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. CRISPR Therapeutics AG stock (CRSP) PE ratio as of Oct 01 2020 is 182.46. More Details
CRISPR Therapeutics AG PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
CRISPR Therapeutics AG PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:BBIO NAS:RARE NAS:GBT NAS:CBPO NAS:NKTR NAS:MRTX NAS:VIR NAS:FTSV NAS:IOVA NAS:CCXI OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address Baarerstrasse 14, Zug, CHE, 6300
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.